WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Saturday, October 20, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email


Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018
Thursday, August 09, 2018

NEW YORK, August 9, 2018 /PRNewswire/ -- The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading companies.

Read the full report: https://www.reportlinker.com/p03605500

Comprehensive directory of personalized medicine in oncology deals since 2012
Personalized medicine in oncology contract documents
Personalized medicine in oncology agreement terms
Personalized medicine in oncology agreement structure
Top personalized medicine in oncology deals by value
Most active personalized medicine in oncology dealmakers

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2012, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2012. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2012. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report scope
Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 includes:
Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2012
Analysis of personalized medicine in oncology deal structure
Case studies of real-life personalized medicine in oncology deals
Access to over 700 personalized medicine in oncology deals
The leading personalized medicine in oncology deals by value since 2012
Most active personalized medicine in oncology dealmakers since 2012
The leading personalized medicine in oncology partnering resources

In Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018, the available contracts are listed by:
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific technology target

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Read the full report: https://www.reportlinker.com/p03605500

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-personalized-medicine-in-oncology-partnering-terms-and-agreements-2012-to-2018-300694977.html

SOURCE Reportlinker



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav ADC Contract Manufacturing Market, 2018-2030: The Capabilities of Contract Services Providers | Oct 19, 2018
Nav Global Animal Medication Markets, 2016-2024: Market Ripe for Consolidation - Zoetis is the Industry Leader | Oct 19, 2018
Nav Global Commercial Biotechnology Separation Systems Market Analysis 2016-2018 & 2024 | Oct 19, 2018
Nav Take a road trip on the spooky side of the street (If you dare!) with a copy of American Road® magazine's Autumn issue | Oct 19, 2018
Nav India City Gas Distribution (CGD) Market 2018: Upcoming Multimillion Dollar Opportunity - Analysing 86 Geographical Areas notified under PNGRB Round IX Bidding | Oct 19, 2018
Nav Real World Evidence (RWE) Solutions Likely to Grow at a CAGR of 14.1% and Significantly Drive Healthcare Decision-making, Predicts Roots Analysis | Oct 18, 2018
Nav NetSuite industry innovations help European businesses accelerate growth | Oct 18, 2018
Nav Global DPP-IV Inhibitors Markets 2016-2024 by Drugs (Sitagliptin, Vildagliptin, Saxagliptin & Others) & Segments (Sitagliptin, Saxagliptin, Linagliptin & Alogliptin) | Oct 17, 2018
Nav Global Cellulosic Man-Made Fibers Business Report 2018: Annual Estimates & Forecasts 2016-2024 - Market Trends & Growth Drivers | Oct 17, 2018
Nav Global Baby Toiletries Strategic Business Report 2018 | Oct 17, 2018
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News